Who owns TFFP - TFF PHARMACEUTICALS INC - COM based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

TFF PHARMACEUTICALS INC - COM (TFFP) Institutional Ownership

Q: What is CUSIP 87241J104?

CUSIP 87241J104 is the security identifier used in SEC filing datasets for TFFP - TFF PHARMACEUTICALS INC - COM.

CUSIP: 87241J104

13F Institutional Holders and Ownership History from Q4 2019 to Q4 2023

Type / Class: Equity / COM
Symbol: TFFP on Nasdaq

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Investment Quick Answers

What is CUSIP 87241J104?
CUSIP 87241J104 identifies TFFP - TFF PHARMACEUTICALS INC - COM in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Continue Investment Research

Latest 13F filings for new institutional portfolio disclosures.
Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
Latest 10-Q/10-K reports to cross-check issuer fundamentals.
Recent insider transactions for management buying/selling context.
SEC investors directory and top value investors for manager-level discovery.
All institutional ownership pages to compare adjacent CUSIP pages.

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 87241J104:

Q4 2023 (0 holders) Q3 2023 (39 holders) Q2 2023 (31 holders) Q1 2023 (35 holders) Q4 2022 (40 holders) Q3 2022 (44 holders) Q2 2022 (44 holders) Q1 2022 (43 holders) Q4 2021 (51 holders) Q3 2021 (53 holders)

Institutional Holders of TFF PHARMACEUTICALS INC - COM (TFFP) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2023 Q4	0	$0	-$4,041,474				0
2023 Q3	11,544,636	$4,041,474	+$1,795,318		$0	$0.35	39
2023 Q2	6,416,076	$3,015,439	-$289,853	$0	$16,168	$0.47	31
2023 Q1	7,000,683	$4,796,887	-$423,234	$2,878	$44,081	$0.69	35
2022 Q4	7,165,988	$7,524,589	+$2,768,389	$20,055	$74,445	$1.05	40
2022 Q3	4,230,845	$17,177,000	-$128,529	$222,000	$174,000	$4.06	44
2022 Q2	4,187,564	$23,663,000	-$736,954	$308,000	$663,000	$5.65	44
2022 Q1	4,298,202	$27,117,000	-$2,431,805	$593,000	$714,000	$6.31	43
2021 Q4	4,638,043	$41,146,000	-$8,799,441	$1,623,000	$886,000	$8.87	51
2021 Q3	5,818,178	$44,903,597	-$18,169	$1,481,000	$958,000	$7.72	53
2021 Q2	5,671,723	$54,498,000	-$22,025,498	$1,596,000	$433,000	$9.61	58
2021 Q1	7,080,725	$96,064,000	+$7,890,934	$1,762,000	$1,747,000	$13.57	61
2020 Q4	6,474,896	$92,807,430	+$15,308,012	$2,047,000	$882,000	$14.32	45
2020 Q3	5,394,010	$99,571,000	+$69,186,580	$1,661,000	$2,372,000	$18.47	39
2020 Q2	1,675,252	$9,649,000	+$3,560,150			$5.76	14
2020 Q1	1,060,662	$4,100,000	+$375,793			$3.84	14
2019 Q4	950,220	$5,085,000	+$5,085,000			$5.35	15